butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Intently. Coadministration of CYP3A4 inducers may well lessen sufentanil amounts and efficacy, quite possibly precipitating withdrawal syndrome in people who may have cre